Novocure has received CE mark approval for Optune Pax, a wearable medical device for adult patients with locally advanced pancreatic cancer of exocrine origin.
The approval covers use of Optune Pax alongside gemcitabine and nab-paclitaxel in accordance with guideline recommendations. Novocure plans to launch the device in Germany in the coming weeks, following US Food and Drug Administration approval earlier this year.
Optune Pax delivers Tumor Treating Fields, alternating electric fields applied non-invasively through wearable arrays. The therapy is designed to disrupt processes critical for cancer cell division and survival while avoiding significant effects on healthy cells. In pancreatic cancer, it is used alongside chemotherapy rather than as a replacement for systemic treatment.
The CE mark is supported by data from the Phase 3 PANOVA-3 trial, which evaluated Optune Pax with gemcitabine and nab-paclitaxel compared with gemcitabine and nab-paclitaxel alone. The trial enrolled 571 patients and met its primary endpoint, showing a statistically significant improvement in median overall survival. Time to pain progression was also significantly extended.
The approval places a wearable electromechanical therapy deeper into one of oncology’s most difficult treatment settings. Pancreatic cancer is frequently diagnosed late, when tumours are more difficult to treat and surgical options may be limited. A device-based therapy used alongside chemotherapy adds a manufacturing, regulatory, and service model distinct from conventional drug supply.
Wearable therapeutic devices combine multiple engineering disciplines. Arrays, adhesives, skin contact materials, power systems, signal generation, control electronics, usability, cleaning, logistics, patient support, and software all affect whether the therapy can be used consistently outside a hospital environment. The product must be clinically effective, manufacturable, maintainable, and usable by patients over extended treatment periods.
The approval sits within a broader movement in medical technology, where electronics and life-science instrumentation are converging. Roche’s sequencing platform, which uses reusable CMOS sensor modules, shows how medical instrumentation is being shaped by semiconductor design, sensor integration, and data processing. Optune Pax has a different clinical purpose, but it reflects the same movement of electronics towards the centre of diagnosis, therapy, and research workflows.
European launch will require market access work with national agencies, patient support infrastructure, device logistics, training, maintenance processes, and monitoring of real-world use. The period after approval can be as demanding as the technical development phase because clinical adoption depends on reimbursement, workflow integration, and consistent supply.
The device also carries a service requirement. Unlike a single-use implant or consumable, wearable therapy involves ongoing patient interaction. Replacement materials, troubleshooting, adherence support, data handling where applicable, and clear communication with clinical teams all influence manufacturing volumes, inventory planning, and quality systems.
Pancreatic cancer treatment places intense pressure on health systems because patient needs are complex and treatment windows can be short. Any therapy introduced into this setting must fit into existing oncology pathways, including chemotherapy scheduling, imaging, symptom management, and palliative support. Device usability affects whether treatment can be delivered as intended.
The CE mark underlines how medical device manufacturing is moving beyond mechanical products and simple electronics. Wearable oncology systems require regulated production, precise control of device output, validated patient-contact materials, and supply chains capable of supporting therapy across multiple markets. The product is both a medical device and an operating model.
Novocure’s next test will be converting approval into access. Germany offers an early launch route, but broader European use will depend on national reimbursement and clinical adoption. Engineered therapies are becoming more prominent in oncology, bringing manufacturing discipline closer to the centre of cancer treatment.
